{"id":17253,"date":"2024-05-03T16:31:11","date_gmt":"2024-05-03T14:31:11","guid":{"rendered":"https:\/\/world-heart-federation.org\/?post_type=news&p=17253"},"modified":"2024-05-08T10:21:04","modified_gmt":"2024-05-08T08:21:04","slug":"it-is-time-to-screen-for-homozygous-familial-hypercholesterolemia-in-the-united-states","status":"publish","type":"news","link":"https:\/\/world-heart-federation.org\/news\/it-is-time-to-screen-for-homozygous-familial-hypercholesterolemia-in-the-united-states\/","title":{"rendered":"It is time to screen for homozygous familial hypercholesterolemia in the United States"},"content":{"rendered":"
The World Heart Federation is excited to celebrate the first-ever HoFH Awareness Day<\/strong> with the international FH and HoFH communities on 4 May 2024.<\/p>\n Homozygous Familial Hypercholesterolemia (HoFH) is an ultra-rare inherited condition characterized by extremely high and life-threatening levels of low-density lipoprotein (LDL) cholesterol from birth, leading to significant premature cardiovascular morbidity and mortality. The disorder affects an estimated 1 in 300,000 people, which amounts to nearly 30,000 individuals worldwide. Alarmingly, data from registries indicate that fewer than 5% of people living with HoFH receive an accurate and timely diagnosis<\/strong>. In the absence of interventions, individuals living with HoFH typically exhibit symptoms of advanced atherosclerotic cardiovascular disease and\/or aortic stenosis before 20 years of age. As such, early detection and adequate treatment are crucial in preventing and managing premature heart disease in affected individuals. In fact, the 2023 Updated European Atherosclerosis Society Consensus Statement on HoFH has, for the first time, recommended screening strategies specific for HoFH that build on current cholesterol screening recommendations.<\/p>\n HoFH remains severely underdiagnosed and undertreated across all countries and regions. In the United States<\/strong>, national guidelines recommend universal pediatric lipid screening in children aged 9-11 years, yet an unacceptably high number of people living with HoFH remain undiagnosed, misdiagnosed, and\/or receive a late diagnosis, often following a major cardiovascular event.<\/p>\n The advent of novel lipid-lowering therapies, along with the realization that diagnosis is too often delayed, has highlighted an urgency to implement policies that ensure timely detection of HoFH in the United States. Evidence from around the world suggests that a combination of universal pediatric screening and cascade screening strategies constitutes an effective approach to identifying heterozygous familial hypercholesterolemia (HeFH), nevertheless, HoFH and its complications manifest much earlier in life compared to HeFH<\/strong>. Unfortunately, little focus has been placed on the detection of HoFH in very young children and\/or infants to date.<\/p>\n